Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03739216 · ClinicalTrials.gov registry record
Registry of Subject Treated With ClariFix
A clinical trial, sponsored by Arrinex.
- Completed
- Registry status
- 354
- Enrollment target
NCT03739216: Completed study, sponsored by Arrinex.
NCT03739216 is a clinical trial that has completed, run by Arrinex. The registered enrollment target is 354 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03739216 has completed, sponsored by Arrinex.
- COMPLETED
- Registry status
- 354 participants
- Enrollment target
Study Summary
A multi-center, prospective, non-randomized, observational registry to asses the results of the ClariFix(TM) device when used to ablate unwanted tissue in the nose of subjects with chronic rhinitis.
Primary Outcome
Effectiveness will be assessed by the change from baseline in nasal symptoms using the TNSS (Total Nasal Symptom Score). The TNSS is a patient-reported assessment of 4 symptom scores for rhinorrhea (runny nose), nasal congestion, nasal itching, and sneezing. Each symptom is rated on a scale of 0 (none) to 3 (severe). The symptom scores are summed to give a total TNSS score that can range from 0 to 12.
Interventions
- DEVICE ClariFix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 354 participants |
| Start Date | 2018-06-13 |
| Est. Completion | 2021-06-15 |
What the finished NCT03739216 record still lists
NCT03739216 is an observational study that tracks outcomes without assigning an intervention. The registered 354 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which ClariFix is the first listed.
NCT03739216 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03739216 about?
NCT03739216 is a clinical study titled "Registry of Subject Treated With ClariFix". A multi-center, prospective, non-randomized, observational registry to asses the results of the ClariFix(TM) device when used to ablate unwanted tissue in the nose of subjects with chronic rhinitis.
What is the current status of trial NCT03739216?
This trial is currently completed. The enrollment target is 354 participants. The study started on 2018-06-13. Estimated completion is 2021-06-15.
What interventions are being tested in trial NCT03739216?
The interventions under investigation include: ClariFix (DEVICE).
Who is sponsoring clinical trial NCT03739216?
This trial is sponsored by Arrinex, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02579967 · 354 participants · Phase 2
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- NCT02610413 · 354 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
- NCT05729256 · 354 participants · NA
Alcohol and "Heat of the Moment" Sexual Decision Making
- NCT06507618 · 354 participants · Phase 3
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI